Galectin Therapeutics Inc Cash Flow Conversion Efficiency
Galectin Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.87 Million) by net assets ($-130.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Galectin Therapeutics Inc (2000–2025)
Cash flow conversion efficiency of Galectin Therapeutics Inc from 2000 to 2025. This chart illustrates how Galectin Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GALT share price today for real-time trading data and today's change.
Galectin Therapeutics Inc Cash Flow Conversion Ratio Explained
Galectin Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Galectin Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galectin Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Galectin Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Career Technology MFG Co Ltd
TW:6153
|
-0.028x |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
0.149x |
|
National Fertilizers Limited
NSE:NFL
|
-0.815x |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
0.054x |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
-0.029x |
|
Guangdong Fangyuan Environment Co. Ltd. A
SHG:688148
|
N/A |
|
BLD Plantation Bhd
KLSE:5069
|
-0.051x |
|
Regional Management Corp
NYSE:RM
|
0.216x |
Annual Cash Flow Conversion Efficiency for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Galectin Therapeutics Inc from 2000 to 2025. Review Galectin Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.19 Million | $-23.88 Million | 0.189x | -53.31% |
| 2024-12-31 | $-103.07 Million | $-41.77 Million | 0.405x | -25.95% |
| 2023-12-31 | $-60.24 Million | $-32.97 Million | 0.547x | -43.27% |
| 2022-12-31 | $-32.19 Million | $-31.06 Million | 0.965x | +110.38% |
| 2021-12-31 | $2.62 Million | $-24.31 Million | -9.292x | -991.22% |
| 2020-12-31 | $24.19 Million | $-20.60 Million | -0.852x | -257.90% |
| 2019-12-31 | $45.59 Million | $-10.85 Million | -0.238x | +83.88% |
| 2018-12-31 | $6.90 Million | $-10.18 Million | -1.476x | +88.92% |
| 2017-12-31 | $1.19 Million | $-15.89 Million | -13.321x | -875.39% |
| 2016-12-31 | $12.02 Million | $-16.41 Million | -1.366x | -101.43% |
| 2015-12-31 | $25.05 Million | $-16.98 Million | -0.678x | -52.64% |
| 2014-12-31 | $27.97 Million | $-12.43 Million | -0.444x | +51.17% |
| 2013-12-31 | $8.23 Million | $-7.48 Million | -0.910x | +3.97% |
| 2012-12-31 | $7.92 Million | $-7.50 Million | -0.947x | +26.61% |
| 2011-12-31 | $4.40 Million | $-5.68 Million | -1.291x | -170.49% |
| 2010-12-31 | $-1.69 Million | $-3.10 Million | 1.831x | +110.44% |
| 2009-12-31 | $-4.47 Million | $-3.89 Million | 0.870x | -91.25% |
| 2008-12-31 | $-469.00K | $-4.67 Million | 9.947x | +430.44% |
| 2007-12-31 | $-2.92 Million | $-5.48 Million | 1.875x | -99.39% |
| 2006-12-31 | $-22.00K | $-6.76 Million | 307.136x | +18060.99% |
| 2005-12-31 | $3.58 Million | $-6.13 Million | -1.710x | -172.85% |
| 2004-12-31 | $10.11 Million | $-6.33 Million | -0.627x | -15.08% |
| 2003-12-31 | $7.62 Million | $-4.15 Million | -0.545x | +70.49% |
| 2002-12-31 | $1.62 Million | $-2.98 Million | -1.845x | -24.69% |
| 2001-12-31 | $1.22 Million | $-1.80 Million | -1.480x | +17.78% |
| 2000-12-31 | $50.00K | $-90.00K | -1.800x | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more